Real-World Safety Analysis of Teclistamab, the B-cell maturation antigen and CD3 bi-specific T-cell engager in patients with relapsed and refractory multiple myeloma: Support for Outpatient Step-Up Dosing Read more
A first-in-human, open label, phase I/II study to evaluate the safety, anti-tumor activity, pharmacokinetics, and pharmacodynamics of SAR446523 monotherapy, an anti-GPRC5D ADCC-enhanced monoclonal antibody in dose escalation and dose optimization, and to evaluate the efficacy of SAR446523 in dose expansion, in participants with relapsed and refractory multiple myeloma. Read more
Outcomes at First Relapse for Patients with Multiple Myeloma who receive Triplet versus Quadruplet Induction Therapy Read more
MMRC Horizon One: A Phase II Randomized adaptive platform Trial evaluating novel therapies in relapsed or refractory multiple myeloma Read more
